Dihexa vs Noopept
A side-by-side research comparison of Dihexa and Noopept across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dihexa | Noopept |
|---|---|---|
| Full name | Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) | Noopept (GVS-111) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Allosteric potentiator of HGF/c-Met signaling driving synaptogenesis, dendritic spine formation, and neuronal survival in hippocampal circuits. | Metabolized to cycloprolylglycine which modulates AMPA/NMDA receptors. Increases NGF and BDNF in hippocampus/cortex. Antioxidant neuroprotection and acetylcholine enhancement. |
| Molecular weight | 507.6 Da | 318.4 Da |
| Half-life | 6-12 hours | 30-60 minutes (active metabolite longer) |
| Bioavailability | Moderate (oral/SubQ) | High (oral/sublingual) |
| Typical dose | 10-20 mg (oral) or 2-5 mg (SubQ) | 10-30 mg |
| Frequency | Daily | 2-3x daily |
| Route | Oral or Subcutaneous | Oral or Sublingual |
Dihexa reported benefits
- Dramatic synaptogenesis
- Memory improvement
- Cognitive restoration potential
- Dendritic spine growth
- HGF/c-Met activation
Noopept reported benefits
- Enhanced memory/learning
- Neuroprotection
- BDNF/NGF increase
- Improved focus
- Anxiolytic
- Low dose requirement
Related comparisons
Research and educational reference only. Not medical advice.